With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5350-41-4,N,N,N-Trimethyl-1-phenylmethanaminium bromide,as a common compound, the synthetic route is as follows.
5350-41-4, [Method A (cations)] Titrationcurves were obtained in CDCl3 at 25 oC, by adding stocksolution of host 1 to a constantconcentration (2 mM) of a guest. Up-field shift of the guest cation, especiallyCH3 or CH2, was observed. Plots of the variations of thechemical shift of the guest upon addition of the titration were registered.[Method B (anions)] Similarly,titration curves were obtained in CDCl3 at 25 oC, byadding stock solution of a guest to a constant concentration (2 mM) of host 1. Since down-field shift of amideprotons of the host 1 was observed,plots of the variations of the chemical shift of the guest upon addition of thetitration were registered.[Estimation of Ka]Titration data were then treated according to a standard binding isotherm forthe case of 1:1 association.2 Non-linear curve fitting usingKaleidaGraph 4.1 (Synergy Software) software package afforded Ka and Ddmax.
5350-41-4 N,N,N-Trimethyl-1-phenylmethanaminium bromide 21449, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Akazome, Motohiro; Hamada, Norihiro; Takagi, Koji; Yagyu, Daisuke; Matsumoto, Shoji; Tetrahedron Letters; vol. 55; 14; (2014); p. 2226 – 2229;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI